Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Biomarker Screening Protocol to Support Preliminary Eligibility for Clinical Trials Evaluating Safety and Efficacy of Adoptive T-cell Therapies in Participants With Solid Tumors

NCT05891197 is registered in ClinicalTrials.gov with Lyell Immunopharma, Inc. as lead sponsor.

NCT NCT05891197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05891197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Biomarker Screening Protocol to Support Preliminary Eligibility for Clinical Trials Evaluating Safety and Efficacy of Adoptive T-cell Therapies in Participants With Solid Tumors
Lead sponsor
Lyell Immunopharma, Inc.
Phase
Observational
Overall status
Terminated
Start date
May 19, 2023
Completion date
February 5, 2025
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, advanced lung carcinoma, endometrial cancer, endometrioid tumor, fallopian tube cancer, high grade serous carcinoma, non small cell lung cancer, non small cell lung cancer metastatic, non-small cell carcinoma of lung, tnm stage 4, non-small cell lung cancer, nsclc, nsclc stage iv, nsclc, recurrent, ovarian cancer, ovarian epithelial cancer, platinum-resistant ovarian cancer, primary peritoneal carcinoma, recurrent breast cancer, recurrent nsclc, relapse/recurrence, relapsed cancer, triple negative breast cancer